You are here:
26 May 2021 / deal

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.



Genoteerd - Spoedprocedures in overnameprocessen

Quoted - Expedited proceedings in takeover processes

The relevant differences between inquiry proceedings and summary proceedings as a means of initiating expedited proceedings in takeover processes. read more
People with blue windows - COMI – Luxembourg technical analysis & Case Law critique

COMI – Luxembourg technical analysis & Case Law critique

This articles deals with the insolvency concept of the center of main interests (COMI) under the European Union insolvency legislation read more
The shareholders of Metri Holding B.V. have sold all their shares in the capital of Metri Holding B.V. to International Data Corporation

The shareholders of Metri Holding B.V.

The shareholders of Metri Holding B.V. have sold all their shares in the capital of Metri Holding B.V. to International Data Corporation read more